Vyome Inc. (HIND)
NASDAQ: HIND
· Real-Time Price · USD
5.17
-0.24 (-4.44%)
At close: Sep 26, 2025, 3:59 PM
5.10
-1.35%
After-hours: Sep 26, 2025, 07:23 PM EDT
Company Description
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets.
The company was founded in 2017 and is based in Princeton, New Jersey.
Vyome Inc.
| Country | United States |
| IPO Date | Oct 6, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Venkateswarlu Nelabhotla |
Contact Details
Address: 100, Overlook Center Princeton, New Jersey United States | |
| Website | https://www.vyometx.com |
Stock Details
| Ticker Symbol | HIND |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001427570 |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul F. Hickey | Chief Executive Officer, President & Director |
| Thomas Stankovich | Senior Vice President & Chief Financial Officer |
| Al Diaz | Vice President of Operations and R&D |
| Dan W. Gladney | Executive Chair |
| Dr. Dov Gal D.V.M., M.B.A. | Vice President of Regulatory Clinical Quality & Compliance Officer |
| Naqeeb A. Ansari | Senior Vice President of Global Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 22, 2025 | 4 | Filing |
| Sep 12, 2025 | 8-K/A | [Amend] Current Report |
| Sep 11, 2025 | 4 | Filing |
| Sep 11, 2025 | 3 | Filing |
| Sep 11, 2025 | 3 | Filing |
| Sep 02, 2025 | 8-K | Current Report |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 20, 2025 | 424B5 | Filing |
| Aug 19, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |